| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2022 | — | Exane BNP Paribas | Initiates Coverage On | → Neutral | |
| 07/15/2022 | -23.66% | UBS | $73 → $59 | Maintains | Neutral |
| 07/05/2022 | -2.96% | Loop Capital | → $75 | Upgrades | Hold → Buy |
| 04/29/2022 | 16.44% | Wedbush | → $90 | Initiates Coverage On | → Outperform |
| 04/04/2022 | 3.51% | Loop Capital | $150 → $80 | Downgrades | Buy → Hold |
| 02/01/2022 | 94.07% | Loop Capital | $190 → $150 | Maintains | Buy |
| 01/26/2022 | 97.96% | B. Riley Securities | $174 → $153 | Maintains | Buy |
| 01/18/2022 | — | Seaport Global | Initiates Coverage On | → Neutral | |
| 09/15/2021 | 125.13% | B. Riley Securities | $152 → $174 | Maintains | Buy |
| 07/22/2021 | 139.36% | Piper Sandler | $143 → $185 | Maintains | Overweight |
| 07/20/2021 | 68.2% | Pivotal Research | $125 → $130 | Maintains | Buy |
| 07/14/2021 | 85.02% | Piper Sandler | $140 → $143 | Maintains | Overweight |
| 06/29/2021 | 70.79% | B. Riley Securities | $113 → $132 | Maintains | Buy |
| 04/27/2021 | 81.14% | Piper Sandler | $104 → $140 | Maintains | Overweight |
| 02/24/2021 | 29.38% | Pivotal Research | $92 → $100 | Maintains | Buy |
| 10/27/2020 | -13.31% | Piper Sandler | $53 → $67 | Maintains | Overweight |
| 10/19/2020 | -37.9% | UBS | $42 → $48 | Maintains | Neutral |
| 10/14/2020 | -31.43% | Piper Sandler | $48 → $53 | Maintains | Overweight |
| 09/29/2020 | -37.9% | Piper Sandler | $46 → $48 | Maintains | Overweight |
| 08/25/2020 | -40.48% | B. Riley Securities | $35 → $46 | Upgrades | Neutral → Buy |
| 07/22/2020 | -48.25% | UBS | → $40 | Initiates Coverage On | → Neutral |
| 07/17/2020 | — | CL King | Downgrades | Buy → Neutral | |
| 06/30/2020 | -48.25% | Loop Capital | $22 → $40 | Upgrades | Hold → Buy |
| 04/06/2020 | -67.65% | Susquehanna | $51 → $25 | Maintains | Positive |
| 02/28/2020 | -44.37% | Baird | $49 → $43 | Maintains | Outperform |
| 10/08/2019 | -56.01% | Piper Sandler | $32 → $34 | Maintains | Overweight |
| 08/02/2019 | -70.24% | Stifel | $21 → $23 | Maintains | Hold |
| 07/15/2019 | -65.07% | Piper Sandler | $22 → $27 | Upgrades | Neutral → Overweight |
| 06/21/2019 | -62.48% | Baird | → $29 | Upgrades | Neutral → Outperform |
| 04/23/2019 | -59.89% | Piper Sandler | → $31 | Downgrades | Overweight → Neutral |
| 01/02/2019 | — | Susquehanna | Upgrades | Neutral → Positive | |
| 11/12/2018 | — | Susquehanna | Upgrades | Negative → Neutral | |
| 07/25/2018 | -72.83% | Pivotal Research | $15 → $21 | Upgrades | Hold → Buy |
| 05/09/2018 | — | Stifel | Downgrades | Buy → Hold | |
| 04/16/2018 | — | Susquehanna | Downgrades | Neutral → Negative | |
| 03/01/2018 | — | Piper Sandler | Upgrades | Neutral → Overweight | |
| 03/01/2018 | -88.36% | Buckingham Research | $7 → $9 | Maintains | Underweight |
| 12/15/2017 | — | Stifel | Upgrades | Hold → Buy | |
| 10/05/2017 | -87.71% | Pivotal Research | → $9.5 | Initiates Coverage On | → Hold |
Crocs Questions & Answers
The latest price target for Crocs (NASDAQ: CROX) was reported by Exane BNP Paribas on September 21, 2022. The analyst firm set a price target for $0.00 expecting CROX to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for Crocs (NASDAQ: CROX) was provided by Exane BNP Paribas, and Crocs initiated their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Crocs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Crocs was filed on September 21, 2022 so you should expect the next rating to be made available sometime around September 21, 2023.
While ratings are subjective and will change, the latest Crocs (CROX) rating was a initiated with a price target of $0.00 to $0.00. The current price Crocs (CROX) is trading at is $77.29, which is out of the analyst's predicted range.